Breaking News

Medpace Acquires European CRO

January 18, 2010

Medpace, a privately held, full-service CRO, has acquired Medical Consulting Dr. Schlichtiger GmbH, a Munich-based CRO that provides customized regulatory and pharmacovigilance services to pharmaceutical, biotechnology and nutritional companies.

Medpace, a privately held, full-service CRO, has acquired Medical Consulting Dr. Schlichtiger GmbH, a Munich-based CRO that provides customized regulatory and pharmacovigilance services to pharmaceutical, biotechnology and nutritional companies.

The acquisition provides Medpace with centralized European hubs for regulatory submissions and approvals as well as drug safety management and reporting. Medical Consulting is led by Dr. Ursula Schlichtiger, general manager and research professional. Dr. Schlichtiger has extensive experience in clinical development, regulatory affairs, and pharmacovigilance.

"I am pleased to have Dr. Schlichtiger join the Medpace team to support our growing presence in the European drug development market as managing director and senior director of Medical and Regulatory Affairs, Europe," said Dr. August Troendle, president and chief executive officer, Medpace. "Dr. Schlichtiger has built a reputation in Europe as a distinguished professional having founded Medical Consulting in 1989 and building the company into an organization widely recognized for their successful interaction with European governmental agencies."

The integration of Medical Consulting Dr. Schlichtiger GmbH will begin immediately and is scheduled for completion in mid-2010. The leaders at Medical Consulting will continue in their current positions.

Related Compliance:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems